IL160141A0 - Novel molecular target for neurotoxicity - Google Patents

Novel molecular target for neurotoxicity

Info

Publication number: IL160141A0
Authority: IL; Israel
Prior art keywords: pde4b; activity; expression; pde4; sequence
Prior art date: 2001-08-14

Application number

IL16014102A

Other languages

English (en)

Original Assignee

Exonhit Therapeutics Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-14

Filing date

2002-08-13

Publication date

2004-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8866536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL160141(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-13 Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa

2004-06-20 Publication of IL160141A0 publication Critical patent/IL160141A0/xx

Links

206010029350 Neurotoxicity Diseases 0.000 title 1
206010044221 Toxic encephalopathy Diseases 0.000 title 1
230000007135 neurotoxicity Effects 0.000 title 1
231100000228 neurotoxicity Toxicity 0.000 title 1
101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 abstract 6
102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 abstract 5
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 3
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
108091026890 Coding region Proteins 0.000 abstract 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 abstract 1
241001529936 Murinae Species 0.000 abstract 1
-1 PDE4B Chemical compound 0.000 abstract 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract 1
241000700159 Rattus Species 0.000 abstract 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
210000001638 cerebellum Anatomy 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000003492 excitotoxic effect Effects 0.000 abstract 1
231100000063 excitotoxicity Toxicity 0.000 abstract 1
102000048114 human PDE4B Human genes 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000005259 measurement Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
210000000944 nerve tissue Anatomy 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
210000002569 neuron Anatomy 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
229960001476 pentoxifylline Drugs 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)

IL16014102A 2001-08-14 2002-08-13 Novel molecular target for neurotoxicity IL160141A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0110819A FR2828693B1 (fr)	2001-08-14	2001-08-14	Nouvelle cible moleculaire de la neurotoxicite
PCT/FR2002/002861 WO2003016563A2 (fr)	2001-08-14	2002-08-13	Cible moleculaire de la neurotoxicite

Publications (1)

Publication Number	Publication Date
IL160141A0 true IL160141A0 (en)	2004-06-20

Family

ID=8866536

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16014102A IL160141A0 (en)	2001-08-14	2002-08-13	Novel molecular target for neurotoxicity
IL160141A IL160141A (en)	2001-08-14	2004-01-29	Molecular target for neurotoxicity for als treatment

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL160141A IL160141A (en)	2001-08-14	2004-01-29	Molecular target for neurotoxicity for als treatment

Country Status (15)

Country	Link
US (1)	US6855736B2 (de)
EP (2)	EP1417349B1 (de)
JP (1)	JP4527395B2 (de)
CN (2)	CN1541278A (de)
AT (2)	ATE414790T1 (de)
AU (1)	AU2002339017B2 (de)
CA (1)	CA2457611C (de)
DE (2)	DE60229953D1 (de)
DK (2)	DK1417349T3 (de)
ES (2)	ES2316625T3 (de)
FR (1)	FR2828693B1 (de)
IL (2)	IL160141A0 (de)
NZ (1)	NZ530939A (de)
PT (2)	PT1982704E (de)
WO (1)	WO2003016563A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040219552A1 (en) *	2001-08-14	2004-11-04	Ali Ait Ikhlef	Novel molecular target for neurotoxicity
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
WO2004042390A2 (en) *	2002-11-08	2004-05-21	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
FR2851247B1 (fr)	2003-02-19	2007-06-29	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de pathologies degeneratives oculaires
ATE337003T1 (de) *	2003-04-28	2006-09-15	Biofrontera Bioscience Gmbh	Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
FR2856595B1 (fr) *	2003-06-27	2008-05-30	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de deficits cognitifs.
US20050079548A1 (en) *	2003-07-07	2005-04-14	Plexxikon, Inc.	Ligand development using PDE4B crystal structures
EP1538218A1 (de) *	2003-12-04	2005-06-08	Erasmus University Medical Center Rotterdam	Verfahren zur Diagnose oder Untersuchung entzündlicher Krankheiten
AU2004299277A1 (en) *	2003-12-19	2005-06-30	Glaxo Group Limited	Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080275078A1 (en) *	2004-03-16	2008-11-06	Glaxo Group Limited	Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
EP1742627A4 (de)	2004-05-06	2009-08-26	Plexxikon Inc	Pde4b-hemmer und ihre verwendung
WO2006026754A2 (en) *	2004-09-03	2006-03-09	Plexxikon, Inc.	Bicyclic heteroaryl pde4b inhibitors
WO2007071437A2 (en) *	2005-12-22	2007-06-28	Ares Trading S.A.	Compositions and methods for treating inflammatory disorders
ES2353093B1 (es) *	2009-05-20	2012-01-03	Consejo Superior De Investigaciones Científicas (Csic)	Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
WO2013140785A1 (ja) *	2012-03-18	2013-09-26	国立大学法人九州大学	疾患サンプル分析装置、分析システム及び分析方法
BR112015019276A2 (pt)	2013-02-19	2017-07-18	Pfizer	compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2016012896A1 (en)	2014-07-24	2016-01-28	Pfizer Inc.	Pyrazolopyrimidine compounds
MD20170011A2 (ro)	2014-08-06	2017-08-31	Pfizer Inc.	Compuşi imidazopiridazinici

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5977305A (en) *	1990-04-20	1999-11-02	Cold Spring Harbor Laboratories	Cloning by complementation and related processes
US5672622A (en) †	1994-04-21	1997-09-30	Berlex Laboratories, Inc.	Treatment of multiple sclerosis
US6060501A (en) *	1994-06-02	2000-05-09	Schering Aktiengesellschaft	Combined treatment of multiple sclerosis
WO1996020281A1 (en) *	1994-12-23	1996-07-04	Celltech Therapeutics Limited	Human phosphodiesterase type ivc, and its production and use
FR2775984B1 (fr)	1998-03-11	2006-09-15	Bioscreen Therapeutics Sa	Criblage differentiel qualitatif
US6548490B1 (en) *	1997-10-28	2003-04-15	Vivus, Inc.	Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1141278B1 (de) *	1998-12-30	2008-02-27	Oligos Etc. Inc.	Therapeutische pde4d phosphodiesterase inhibitoren
US6334998B1 (en) *	1999-12-07	2002-01-01	Parker Hughes Institute	Estrogens for treating ALS
WO2001044449A1 (en) *	1999-12-14	2001-06-21	University Of Utah Research Foundation	TWO NOVEL cAMP-SPECIFIC PHOSPHODIESTERASE (PDE4B) ISOFORMS AND RELATED TECHNOLOGY
US20030060487A1 (en) †	2000-04-12	2003-03-27	Bamdad R. Shoshana	Treatment of neurodegenerative disease
JP2002020386A (ja) †	2000-07-07	2002-01-23	Ono Pharmaceut Co Ltd	ピラゾロピリジン誘導体
FR2856595B1 (fr) †	2003-06-27	2008-05-30	Exonhit Therapeutics Sa	Methodes et compositions pour le traitement de deficits cognitifs.

2001
- 2001-08-14 FR FR0110819A patent/FR2828693B1/fr not_active Expired - Fee Related
- 2001-10-25 US US09/983,754 patent/US6855736B2/en not_active Expired - Fee Related
2002
- 2002-08-13 DK DK02777405T patent/DK1417349T3/da active
- 2002-08-13 NZ NZ530939A patent/NZ530939A/en not_active IP Right Cessation
- 2002-08-13 DE DE60229953T patent/DE60229953D1/de not_active Expired - Lifetime
- 2002-08-13 EP EP02777405A patent/EP1417349B1/de not_active Expired - Lifetime
- 2002-08-13 AT AT02777405T patent/ATE414790T1/de active
- 2002-08-13 CN CNA028158407A patent/CN1541278A/zh active Pending
- 2002-08-13 EP EP08160783.0A patent/EP1982704B2/de not_active Expired - Lifetime
- 2002-08-13 WO PCT/FR2002/002861 patent/WO2003016563A2/fr not_active Ceased
- 2002-08-13 AT AT08160783T patent/ATE476530T1/de active
- 2002-08-13 DE DE60237248T patent/DE60237248D1/de not_active Expired - Lifetime
- 2002-08-13 PT PT08160783T patent/PT1982704E/pt unknown
- 2002-08-13 AU AU2002339017A patent/AU2002339017B2/en not_active Ceased
- 2002-08-13 ES ES02777405T patent/ES2316625T3/es not_active Expired - Lifetime
- 2002-08-13 DK DK08160783.0T patent/DK1982704T3/da active
- 2002-08-13 ES ES08160783T patent/ES2348348T5/es not_active Expired - Lifetime
- 2002-08-13 PT PT02777405T patent/PT1417349E/pt unknown
- 2002-08-13 IL IL16014102A patent/IL160141A0/xx unknown
- 2002-08-13 CN CN2009101342838A patent/CN101632663B/zh not_active Expired - Fee Related
- 2002-08-13 JP JP2003521870A patent/JP4527395B2/ja not_active Expired - Fee Related
- 2002-08-13 CA CA2457611A patent/CA2457611C/fr not_active Expired - Fee Related
2004
- 2004-01-29 IL IL160141A patent/IL160141A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2005500066A (ja)	2005-01-06
DK1417349T3 (da)	2009-03-23
US20030064374A1 (en)	2003-04-03
EP1417349A2 (de)	2004-05-12
ES2348348T3 (es)	2010-12-03
CA2457611C (fr)	2013-04-02
DE60237248D1 (de)	2010-09-16
EP1982704A3 (de)	2008-12-17
JP4527395B2 (ja)	2010-08-18
US6855736B2 (en)	2005-02-15
PT1417349E (pt)	2009-02-09
ES2348348T5 (es)	2013-12-04
EP1417349B1 (de)	2008-11-19
CN1541278A (zh)	2004-10-27
WO2003016563A3 (fr)	2004-04-01
CN101632663A (zh)	2010-01-27
DK1982704T3 (da)	2010-10-04
PT1982704E (pt)	2010-10-11
EP1982704B2 (de)	2013-07-24
FR2828693A1 (fr)	2003-02-21
IL160141A (en)	2010-12-30
FR2828693B1 (fr)	2004-06-18
AU2002339017B2 (en)	2007-11-01
EP1982704A2 (de)	2008-10-22
WO2003016563A2 (fr)	2003-02-27
EP1982704B1 (de)	2010-08-04
ES2316625T3 (es)	2009-04-16
CA2457611A1 (fr)	2003-02-27
NZ530939A (en)	2006-11-30
DE60229953D1 (de)	2009-01-02
CN101632663B (zh)	2011-11-30
ATE476530T1 (de)	2010-08-15
ATE414790T1 (de)	2008-12-15

Publication	Publication Date	Title
IL160141A0 (en)	2004-06-20	Novel molecular target for neurotoxicity
WO2001078711A3 (en)	2002-07-04	Pde-v inhibitors for treatment of parkinson's disease
AP2004003069A0 (en)	2004-06-30	3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
ZA200809250B (en)	2010-02-24	Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
SI1567488T1 (sl)	2007-08-31	Derivati hidroksietilamina za zdravljenje alzheimerjeve bolezni
WO2008011476A3 (en)	2008-12-31	Compositions and methods for modulating sirtuin activity
GB9716656D0 (en)	1997-10-15	Chemical compounds
EP1562897A4 (de)	2007-06-27	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
TNSN07208A1 (en)	2008-11-21	3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
TR200102782T2 (tr)	2002-04-22	Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
MY134783A (en)	2007-12-31	Rho-kinase inhibitors
MY142915A (en)	2011-01-31	Rho-kinase inhibitors
PT1696905E (pt)	2008-06-09	2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
MXPA05009535A (es)	2005-11-16	Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
ATE357438T1 (de)	2007-04-15	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
AU2002363182A1 (en)	2003-05-12	Smad7 inhibitors for the treatment of cns diseases
PL377715A1 (pl)	2006-02-06	Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
SG151336A1 (en)	2009-04-30	1,3,4-oxadiazol-2-ones as ppar delta
MA28562B1 (fr)	2007-04-03	1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
ATE310517T1 (de)	2005-12-15	Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
PT1255734E (pt)	2006-09-29	Derivados de isatina com actividade neurotrofica
DE69928814D1 (de)	2006-01-12	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
WO2004038405A3 (en)	2004-09-30	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
EP1784204A4 (de)	2008-11-05	Verfahren zur herstellung, prävention, hemmung oder verringerung von schäden an herzgewebe
WO2004038421A3 (en)	2004-06-24	Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)